Rechercher des projets européens

11 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

European AIDS Vaccine Initiative 2020 (EAVI2020)

Date du début: 1 nov. 2015, Date de fin: 31 oct. 2020,

HIV-1 is responsible for a global pandemic of 35 million people, and continues to spread at a rate of >2 million new infections/year. It is widely acknowledged that a protective vaccine would be the most effective means to reduce HIV-1 spread and ultimately eliminate the pandemic, while a therapeutic vaccine may help mitigate the clinical course of disease and lead to strategies of viral eradicati ...
Voir le projet

 27

 TERMINÉ 

Common Oncogenic Mechanisms in Multi-Partner Translocation Families in Acute Myeloid Leukemia (ONCOMECHAML)

Date du début: 1 juin 2015, Date de fin: 31 mai 2020,

Acute Myeloid Leukemia (AML) is the most frequent cancer of the blood system, with >80% mortality within 5 years of diagnosis. Straightforward clinical decisions are complicated by the genetic complexity of AML. In particular, fusion proteins arising from chromosomal aberrations are recurrently found in AML and often act as strong driver oncogenes. In “Multi-Partner Translocation” (MPT) families, ...
Voir le projet

 1

 TERMINÉ 

Advanced Regenerative and REStorative Therapies to combat corneal BLINDNESS (ARREST BLINDNESS)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,

Over 30 million Europeans are blind or visually impaired, leading to reduced quality of life and a tremendous loss of productivity in society. Corneal blindness is the second largest cause of blindness globally and while treatable, millions remain unnecessarily blind due to issues of access to transplantable tissue, lack of standardized treatments, and the lag in translating new regenerative medic ...
Voir le projet

 14

 TERMINÉ 

ALK Activation as a target of TRAanslational Science (ALKATRAS): Break free from cancer (ALKATRAS)

Date du début: 1 sept. 2015, Date de fin: 31 août 2019,

This ETN is embedded into an established international research programme; The European Research Initiative on Anaplastic Lymphoma Kinase (ALK)-related malignancies (ERIA; www.erialcl.net) is an existing and functional network of 13 partners, which will cosset and nurture a cohort of early stage researchers to become confident, competent, independent and well-connected European scientists with exc ...
Voir le projet

 13

 TERMINÉ 

Rational Bioactive Materials Design for Tissue Regeneration (BIODESIGN)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2016,

The development of functional materials for tissue regeneration is today mostly based on perceived and limited design criteria often using a single point approach with lengthy animal trials. The outcome after in-vitro and in-vivo evaluation is often disappointing resulting in a tedious iteration process. The main objective of this project is to achieve radical innovations in state-of-the-art bioma ...
Voir le projet

 21

 TERMINÉ 

Regime and Society in Eastern Europe (1956 - 1989). From Extended Reproduction to Social and Political Change (RESOCEA)

Date du début: 1 juin 2011, Date de fin: 31 mai 2016,

"The ambition of this project rests on the long-established tradition of the comparative politico-historical and interdisciplinary studies of the totalitarian regimes and on the theoretical efforts to elucidate the social dynamics and social change in Eastern Europe during the so called ""real socialism"". It will deal with the relations between regime and society in an attempt to highlight the gr ...
Voir le projet

 7

 TERMINÉ 

Enhancing the (cost-)effectiveness of diabetes self-management education: A comparative assessment of different educational approaches and conditions for successful implementation (DIABETES LITERACY)

Date du début: 1 nov. 2012, Date de fin: 31 déc. 2015,

The project aims to contribute to building the evidence base to increase the effectiveness of diabetes self-management education in the EU Member States, as part of a comprehensive diabetes strategy at EU level. To that effect, it will perform a systematic and comparative content analysis of the national diabetes strategies and frameworks across the 27 EU MS, establish a compendium of diabetes sel ...
Voir le projet

 9

 TERMINÉ 

Adopting Hospital Based Health Technology Assessment in EU (AdHopHTA)

Date du début: 1 sept. 2012, Date de fin: 30 nov. 2015,

The use of HTA as a part of the decision-making process at national, regional, and international levels has evolved considerably over the past 35 years. However, still an important number of good-value innovative HTs never reach clinical practice while, in many instances, others with no significant added value actually do. This situation can be effectively overcome by approaching HTA at hospital l ...
Voir le projet

 11

 TERMINÉ 

Biomimetic and Biomineralized Magnetic Nanoparticles for Magnetic Resonance Imaging (Bio2MaN4MRI)

Date du début: 1 sept. 2011, Date de fin: 31 août 2014,

Nanoscience and nanotechnology are currently revolutionizing sectors such as medicine, information technologies, environmental or materials sciences, and creating new opportunities for our societies. In this context, magnetic nanoparticles (MNP) are key components to the development of novel nano- and biotechnologies. Magnetosomes are unique hybrid magnetic MNP produced by magnetotactic bacteria ( ...
Voir le projet

 8

 TERMINÉ 

Angiogenesis-inducing Bioactive and Bioresponsive Scaffolds in Tissue Enginering (AngioScaff)

Date du début: 1 déc. 2008, Date de fin: 30 nov. 2012,

Angiogenesis underlies almost all biological processes of morphogenesis, including those in tissue repair and regeneration. Physiological angiogenesis is controlled by a complex interplay between cells and their environment: the extracellular matrix (ECM) provides signaling via numerous ECM adhesion molecules and growth factors bound to ECM polysaccharide components; and cells locally degrade and ...
Voir le projet

 33

 TERMINÉ 

Establishment of a novel CML model using Multi-Hit technology (CMLMULTIHIT)

Date du début: 17 mai 2010, Date de fin: 16 mai 2012,

"The chronic phase of chronic myeloid leukaemia (CML) is characterized by the expression of the chimeric BCR-ABL gene, extended survival, and profligate growth of maturing granulocyte stemline. It provided the rationale for producing first imatinib and then a series of small molecules designed to inhibit the tyrosine kinase activity of the BCR-ABL oncoprotein, all of which can induce complete cyto ...
Voir le projet

 1